Ligand Pharmaceuticals | LGND - Sales Revenues


Ligand Pharmaceuticals reported $115.46M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Amgen USD 9.9B 340M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Baxter International USD 2.84B 30M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.8B 700M Sep/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Insmed USD 142M 34.6M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Ligand Pharmaceuticals USD 115.46M 67.83M Sep/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Pacira USD 179.52M 1.58M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Veracyte USD 131.9M 1.74M Sep/2025